IgA Nephropathy Clinical Trials

15 recruiting

IgA Nephropathy Trials at a Glance

35 actively recruiting trials for iga nephropathy are listed on ClinicalTrialsFinder across 6 cities in 39 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Beijing, Houston, and Guangzhou. Lead sponsors running iga nephropathy studies include The Children's Hospital of Zhejiang University School of Medicine, Ruijin Hospital, and Haisco Pharmaceutical Group Co., Ltd..

Browse iga nephropathy trials by phase

Treatments under study

About IgA Nephropathy Clinical Trials

Looking for clinical trials for IgA Nephropathy? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new IgA Nephropathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about IgA Nephropathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 35 trials

Recruiting
Phase 2

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

IgA Nephropathy (IgAN)IgANC3G+2 more
ADARx Pharmaceuticals, Inc.45 enrolled25 locationsNCT06989359
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Primary IgA Nephropathy
Hoffmann-La Roche428 enrolled202 locationsNCT05797610
Recruiting

IgA Nephropathy Biomarkers Evaluation Study (INTEREST)

IgA NephropathyGlomerular Diseases
Sun Yat-sen University2,000 enrolled1 locationNCT02954419
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Phase 1

Study of BHV-1400 in IgA Nephropathy

IgA Nephropathy
Biohaven Therapeutics Ltd.20 enrolled12 locationsNCT07054684
Recruiting
Phase 3

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting
Phase 4

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

IgA Nephropathy
Calliditas Therapeutics AB60 enrolled38 locationsNCT06712407
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07305116
Recruiting
Phase 3

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.370 enrolled1 locationNCT07390123
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

IgA Nephropathy (IgAN)Membranous NephropathyANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN)+2 more
Grit Biotechnology30 enrolled1 locationNCT07389499
Recruiting

A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy

IgA Nephropathy (IgAN)Early Initial Therapy
Sichuan Provincial People's Hospital200 enrolled1 locationNCT06676007
Recruiting
Phase 2

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

IgA Nephropathy (IgAN)
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.30 enrolled1 locationNCT07305974
Recruiting
Early Phase 1

Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease

Autoimmune DiseasesSystemic Lupus ErthematosusMulti-Drug Resistant Nephrotic Syndrome+1 more
The Children's Hospital of Zhejiang University School of Medicine36 enrolled1 locationNCT06792799
Recruiting
Phase 2

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

IgA Nephropathy (IgAN)
Mayo Clinic16 enrolled2 locationsNCT06676579
Recruiting
Phase 4

Nefecon and Ambrisentan in IgA Nephropathy

Chronic Kidney DiseaseIgA NephropathyProteinuria
The First Hospital of Jilin University129 enrolled1 locationNCT07030894
Recruiting

Study of the Link Between Complement Activation and IgA Nephropathy Severity

IgA Nephropathy Severity in Kidney Transplantation
University Hospital, Strasbourg, France400 enrolled1 locationNCT05234463
Recruiting
Phase 3

A Trial of HRS-5965 Capsule in Primary IgA Nephropathy

Primary IgA Nephropathy
Chengdu Suncadia Medicine Co., Ltd.378 enrolled1 locationNCT07014826
Recruiting

RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)

IgA Nephropathy (IgAN)
Assistance Publique - Hôpitaux de Paris800 enrolled1 locationNCT06926244
Recruiting
Phase 4

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

IgA NephropathyRenal Insufficiency, ChronicIgA Vasculitis+1 more
Christian Medical College, Vellore, India585 enrolled12 locationsNCT06676384
Recruiting
Not Applicable

Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial

IgA Nephropathy (IgAN)
Botkin Hospital30 enrolled1 locationNCT07056595